Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Shahram Jacobs MD Inc

Neither a doctor nor a teaching hospital

Research payments

$1,100,341

77 payments

Through program year 2025, Shahram Jacobs MD Inc is reported as receiving $1,100,341 in research payments, across 77 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $64,294 1
2024 Research $75,496 4
2023 Research $50,779 9
2022 Research $119,295 11
2020 Research $70,712 19
2019 Research $719,765 33

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $694,123 3 payments
  2. AbbVie, Inc. $136,071 17 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $115,738 2 payments
  4. Boehringer Ingelheim International GmbH $93,049 47 payments
  5. Acrotech Biopharma LLC $42,606 5 payments
  6. Janssen Research & Development, LLC $15,450 1 payment
  7. GlaxoSmithKline, LLC. $3,305 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-To-Severe Plaque Psoriasis $694,123 3 payments
  2. A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) $118,955 11 payments
  3. Comparative study in Psoriasis $93,049 47 payments
  4. TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis $64,294 1 payment
  5. A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects with Moderate-to-Severe Plaque Psoriasis $51,444 1 payment
  6. 246-13651-301 $42,606 5 payments
  7. A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) $17,116 6 payments
  8. A Phase 2b Multicenter, Randomized, Double-blind, Placebo-controlled Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-81241459 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis $15,450 1 payment
  9. A Phase 3 Randomized, Open-Label (Sponsor-Blind), Active-Controlled, P $3,305 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record